Literature DB >> 7318144

Quantitative association between the in vitro human tumor stem cell assay and clinical response to cancer chemotherapy.

T E Moon, S E Salmon, C S White, H S Chen, F L Meyskens, B G Durie, D S Alberts.   

Abstract

Objective methods have been developed to quantitate results of the in vitro human tumor stem cell assay, the degree of the association between the in vitro assay and clinical response as well as the likelihood of response. Methods considered to quantitate in vitro assay data included first-order kinetics of percent survival with drug concentration, minimal percent of tumor colony-forming unit survival at low drug concentrations, and area under the in vitro percent survival-drug concentration curve. Based upon experimental data, the percent tumor colony survival and the area under the curve (i.e., in vitro sensitivity indices) were concluded to better account than other methods for the commonly observed nonlinear shape of the in vitro curves. The two methods also yielded equivalent quantitative descriptions of the in vitro data. A logistic regression model was used for explicit quantitation of the relationship between the in vitro sensitivity index and predicted probability of clinical response. Very high association was observed between the predicted in vivo and actual clinical response for the cytotoxic drugs considered. Incorporation of other pharmacologic and patient prognostic factors into the quantitative methods is discussed and shown to improve their effectiveness.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7318144     DOI: 10.1007/bf00256973

Source DB:  PubMed          Journal:  Cancer Chemother Pharmacol        ISSN: 0344-5704            Impact factor:   3.333


  14 in total

1.  Primary bioassay of human myeloma stem cells.

Authors:  A Hamburger; S E Salmon
Journal:  J Clin Invest       Date:  1977-10       Impact factor: 14.808

2.  Preparation of permanent slides of intact soft-agar colony cultures of hematopoietic and tumor stem cells.

Authors:  S E Salmon; R N Buick
Journal:  Cancer Res       Date:  1979-03       Impact factor: 12.701

3.  Development of a bioassay for putative human lymphoma stem cells.

Authors:  S E Jones; A W Hamburger; M B Kim; S E Salmon
Journal:  Blood       Date:  1979-02       Impact factor: 22.113

4.  Initial experience with the human tumor stem cell assay system: potential and problems.

Authors:  D D Von Hoff; G J Harris; G Johnson; D Glaubiger
Journal:  Prog Clin Biol Res       Date:  1980

5.  Cellular kinetics in multiple myeloma. A new approach to staging and treatment.

Authors:  S E Salmon; B G Durie
Journal:  Arch Intern Med       Date:  1975-01

6.  Clinical correlations of drug sensitivity in the human tumor stem cell assay.

Authors:  S E Salmon; D S Alberts; B G Durie; F L Meyskens; S E Jones; B Soehnlen; H S Chen; T Moon
Journal:  Recent Results Cancer Res       Date:  1980

7.  Pretreatment tumor mass, cell kinetics, and prognosis in multiple myeloma.

Authors:  B G Durie; S E Salmon; T E Moon
Journal:  Blood       Date:  1980-03       Impact factor: 22.113

8.  Mitomycin C, vincristine, and bleomycin therapy for advanced cervical cancer.

Authors:  L H Baker; M I Opipari; H Wilson; R Bottomley; C A Coltman
Journal:  Obstet Gynecol       Date:  1978-08       Impact factor: 7.661

9.  Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs.

Authors:  S E Salmon; A W Hamburger; B Soehnlen; B G Durie; D S Alberts; T E Moon
Journal:  N Engl J Med       Date:  1978-06-15       Impact factor: 91.245

10.  Primary bioassay of human tumor stem cells.

Authors:  A W Hamburger; S E Salmon
Journal:  Science       Date:  1977-07-29       Impact factor: 47.728

View more
  20 in total

1.  Interstitial chemotherapy with mitoxantrone in recurrent malignant glioma: preliminary data.

Authors:  A Boiardi; A Salmaggi; A Pozzi; G Broggi; A Silvani
Journal:  J Neurooncol       Date:  1996-02       Impact factor: 4.130

2.  Chemosensitivity study of urological malignancies using a novel dye-exclusion method.

Authors:  K Naito; H Hisazumi; S Mihara; T Asari; K Kobashi; T Amano; T Uchibayashi
Journal:  Cancer Chemother Pharmacol       Date:  1987       Impact factor: 3.333

3.  A rapid bioassay to determine stabilities of anticancer agents under conditions of the clonogenic assay.

Authors:  S U Hildebrand-Zanki; D H Kern
Journal:  In Vitro Cell Dev Biol       Date:  1986-05

4.  Potential limitations of in vitro clonogenic drug sensitivity assays.

Authors:  G W Dong; H D Preisler; R Priore
Journal:  Cancer Chemother Pharmacol       Date:  1984       Impact factor: 3.333

5.  Pharmacologic studies of anticancer drugs with the human tumor stem cell assay.

Authors:  D S Alberts; S E Salmon; H S Chen; T E Moon; L Young; E A Surwit
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

6.  Human tumor clonogenic assays. An overview.

Authors:  B I Sikic; R L Taber
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

7.  Sectional analysis of tumor colony growth in the soft-agar assay: effects of oxygen.

Authors:  D Fan; S Fan; L R Morgan
Journal:  J Cancer Res Clin Oncol       Date:  1984       Impact factor: 4.553

8.  Adriamycin and cytosine arabinoside contribute equally to prediction of response in acute myelocytic leukemia with improved confidence level.

Authors:  M G Lihou; P J Smith
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

9.  In vitro cloning of tumor stem cells in semi-solid media containing agar and agarose.

Authors:  O Bagasra; W Berman; S Hashemi; A Howeedy; H Kushner
Journal:  Cancer Immunol Immunother       Date:  1985       Impact factor: 6.968

10.  Chemotherapy of ovarian cancer directed by the human tumor stem cell assay.

Authors:  D S Alberts; H S Chen; S E Salmon; E A Surwit; L Young; T E Moon; F L Meyskens
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.